OurBrainBank Wins Forbes EQ BrandVoice 2024: First Article Features Jessica Morris’s book
OBB founder Jessica Morris’s book is excerpted by Forbes.
Read more
UK ranks 22nd out of 29 comparable countries for survival of Brain Cancer
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
Experimental GBM treatment — DC Vax — is hoped to be moving forward in the UK
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
White House Cancer Moonshot
OurBrainBank is proud that the White House invited us to be part of the ambitious Cancer Moonshot effort. Read the latest from Washington DC.
OurBrainBank at SNO — Society for Neuro-Oncology — Annual Conference
Executive Director Kelli Duprey presented our poster about treatment disparities at SNO 2023
Clinical trial for people newly diagnosed with glioblastoma
Clinical trial for people newly diagnosed with glioblastoma
Stanford Researchers look to Artificial Intelligence to help plan GBM treatment
Model could help doctors identify patients with cellular characteristics that indicate more aggressive tumors, and flag them for accelerated follow-up.
Op-ed by Board Member Sundas Hashmi
There’s a ticking time bomb in my head. I’m learning to live with it.
Like most people in treatment for brain tumors in the United States, I’ve had to adapt to a mind that feels very different from the one I once knew.
Two substantial health reports are released today in the UK.
Two substantial health reports are out today in the UK.
Demand More! Help us make the Glioblastoma Bill of Rights a reality
Our survey showed serious disparities in GBM care across the USA. Let’s tell the country and make change!
OurBrainBank IN THE NEWS.
TAGS.
SUBSCRIBE TO OUR NEWSLETTER
GET INVOLVED
